Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Li… Read more
Pharmosa Biopharm Inc. (6875) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.034x
Based on the latest financial reports, Pharmosa Biopharm Inc. (6875) has a cash flow conversion efficiency ratio of -0.034x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-66.84 Million) by net assets (NT$1.99 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharmosa Biopharm Inc. - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Pharmosa Biopharm Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pharmosa Biopharm Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharmosa Biopharm Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
0.066x |
|
CH Biotech R&D Co., Ltd.
TW:6534
|
-0.042x |
|
Circus SE
XETRA:CA1
|
N/A |
|
Gamehost Inc
PINK:GHIFF
|
0.058x |
|
Asia Plus Group Holdings PCL
BK:ASP
|
0.253x |
|
DEFAMA Deutsche Fachmarkt AG
XETRA:DEF
|
0.065x |
|
Nextensa NV
BR:NEXTA
|
-0.128x |
|
Fiera Milano SpA
F:FM3
|
N/A |
Annual Cash Flow Conversion Efficiency for Pharmosa Biopharm Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Pharmosa Biopharm Inc. from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | NT$1.14 Billion | NT$42.42 Million | 0.037x | +110.99% |
| 2022-12-31 | NT$761.12 Million | NT$-258.31 Million | -0.339x | +24.06% |
| 2021-12-31 | NT$531.43 Million | NT$-237.51 Million | -0.447x | +0.04% |
| 2020-12-31 | NT$405.83 Million | NT$-181.45 Million | -0.447x | -- |